Advertisement

Acta Neuropathologica

, Volume 134, Issue 4, pp 675–677 | Cite as

A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours

  • Evelina Sjöstedt
  • Jens Bollerslev
  • Jan Mulder
  • Cecilia Lindskog
  • Fredrik Pontén
  • Olivera Casar-Borota
Correspondence

Pituitary adenomas, or pituitary neuroendocrine tumours (PitNETs) according to a recent proposal [1], are classified based on expression of the anterior lobe pituitary hormones (ACTH, GH, Prolactin, TSH, FSH, LH and alpha-subunit of the glycoprotein hormones) [2]. Cell differentiation in the adenohypophysis includes three main lineages, each dependent on specific transcription factors: T-Pit (T-box family member TBX19) regulates the proopiomelanocortin (POMC) lineage giving origin to the corticotrophs; Pit-1 determines the fate of somatotroph, lactotroph and thyrotroph cells, while development of FSH- and LH-producing gonadotrophs is regulated by SF-1 (steroidogenic factor-1) and GATA-2 [3, 4]. The nuclear expression of the pituitary specific transcription factors T-Pit, Pit-1 and SF-1 is retained in the pituitary tumour cells that are differentiated towards respective pituitary cell lineages and thus serves as a useful complement in the classification of PitNETs [2]. PitNETs lacking...

Notes

Acknowledgements

This work was supported by The Swedish Cancer Society, Knut and Alice Wallenberg foundation and ALF-funding from the Uppsala University Hospital in Uppsala.

Compliance with ethical standards

Conflict of interest

Fredrik Pontén is a co-founder of Atlas Antibodies. The other authors have no conflicts of interest to disclose.

Ethical standards

All patients whose tumour tissues have been used in the study provided written informed consent, and the regional ethical committee approved the project.

Supplementary material

401_2017_1768_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 17 kb)

References

  1. 1.
    Asa SL, Casar-Borota O, Chanson P et al (2017) From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 24:C5–C8CrossRefPubMedGoogle Scholar
  2. 2.
    Osamura RY, Grossman A, Korbonits M et al (2017) Pituitary adenomas. In: Lloyd RV, Osamura RY, Klöppel G et al (eds) World health organization classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon, pp 14–18Google Scholar
  3. 3.
    Lamolet B, Pulichino AM, Lamonerie T et al (2001) A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104:849–859CrossRefPubMedGoogle Scholar
  4. 4.
    Scully KM, Rosenfeld MG (2002) Pituitary development: regulatory codes in mammalian organogenesis. Science 295:2231–2235CrossRefPubMedGoogle Scholar
  5. 5.
    Uhlen M, Fagerberg L, Hallstrom BM et al (2015) Proteomics. tissue-based map of the human proteome. Science 347:1260419CrossRefPubMedGoogle Scholar
  6. 6.
    Uhlen M, Hallstrom BM, Lindskog C et al (2016) Transcriptomics resources of human tissues and organs. Mol Syst Biol 12:862CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Casar-Borota O, Oystese KA, Sundstrom M et al (2016) A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas. Pituitary 19:407–414CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Science for Life LaboratoryKTH-Royal Institute of TechnologyStockholmSweden
  2. 2.Department of Immunology, Genetics and PathologyUppsala UniversityUppsalaSweden
  3. 3.Department of Specialized EndocrinologyRikshospitalet, Oslo University HospitalOsloNorway
  4. 4.Faculty of MedicineUniversity of OsloOsloNorway
  5. 5.Department of Clinical PathologyUppsala University HospitalUppsalaSweden
  6. 6.Department of PathologyOslo University HospitalOsloNorway

Personalised recommendations